Premium
Which outcomes are reported in cellulitis trials? Results of a review of outcomes included in cellulitis trials and a patient priority setting survey
Author(s) -
Smith E.,
Patel M.,
Thomas K.S.
Publication year - 2018
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.16235
Subject(s) - cellulitis , medicine , clinical trial , medline , intensive care medicine , surgery , political science , law
Summary Background There is an emerging need to develop consistent outcomes in clinical trials to allow effective comparison of treatment effects. No systematic review has previously looked at the reporting of outcome measures used in randomized controlled trials ( RCT s) on the treatment and prevention of cellulitis (erysipelas). Objectives The primary aim of this review was to describe the breadth of outcomes reported from RCT s on cellulitis treatment and prevention. The secondary aim was to identify outcome themes from patients’ and healthcare professionals’ feedback from a cellulitis Priority Setting Partnership ( PSP ). Methods We conducted a review of all outcome measures used in RCT s from two recent Cochrane reviews. Free‐text responses from a cellulitis priority setting survey were used to understand the perspectives of patients and healthcare professionals. Results Outcomes from 42 RCT s on treatment of cellulitis and six RCT s on prevention of cellulitis were reviewed. Only 28 trials stated their primary outcome. For trials assessing treatment of cellulitis, clinical response to treatment was categorized in 25 different ways. Five of these trials used an outcome that was in accordance with FDA guidance and only four trials incorporated either quality of life or patient satisfaction. For trials assessing prevention of cellulitis, recurrence was the key outcome measure. From the cellulitis PSP , prevention of recurrence, clinical features and long‐term disease impact were the most important outcome themes for patients. Conclusions We have shown that in cellulitis treatment and prevention research, there is significant heterogeneity in clinical outcomes, inadequate focus on patient‐reported outcomes, and a disparity between what is currently measured and what patients and healthcare professionals feel is important. We recommend that future cellulitis treatment trials consider the use of longer‐term outcomes to capture recurrence and long‐term morbidity, as well as short‐term resolution of acute infection.